DAPA MITO
Regulation of Hepatic and Peripheral Glucose Metabolism: Protocol IVA. Effect of Plasma Glucose Reduction by Selective SLGT2 Inhibition on Mitochondrial Dysfunction and Impaired Insulin Signaling/Sensitivity in T2DM
Sponsor study identifier
Secondary identifiers
NIH
interventional
18
1 country
1
Study Start
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 30, 2018
Actual (reported)Study Completion
June 30, 2018
Actual (reported)The purpose of this study is to examine the effect of the chronic treatment of type 2 diabetes (T2DM) with dapagliflozin on: (1) mitochondrial gene function/expression and insulin signaling/action and (2) oral glucose tolerance and beta cell function. Dapagliflozin is a potent, highly specific inhibitor of renal glucose transport \[SGLT2\].
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
June 30, 2018
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
August 3, 2011
Actual (reported)September 23, 2011
Actual (reported)June 30, 2018
Actual (reported)June 30, 2018
Actual (reported)October 29, 2019
Actual (reported)Change in Insulin Sensitivity
The change in insulin sensitivity and total glucose disposal measured at two weeks with the insulin clamp compared to baseline. This is measured using TGD (whole body tissue glucose disposal)/SSPI (steady state plasma insulin concentration) ratio
baseline, two weeks
Change in Mitochondrial Function
baseline, two weeks
this arm is control
Interventional arm
Treatment arm, 10 mg per day for 2 weeks
Patients are treated with placebo
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Diabetes Division, UTHSCSA
San Antonio, Texas, 78229, United States
Daniele G, Xiong J, Solis-Herrera C, Merovci A, Eldor R, Tripathy D, DeFronzo RA, Norton L, Abdul-Ghani M. Dapagliflozin Enhances Fat Oxidation and Ketone Production in Patients With Type 2 Diabetes. Diabetes Care. 2016 Nov;39(11):2036-2041. doi: 10.2337/dc15-2688. Epub 2016 Aug 25.
Ralph DeFronzo, MD
The University of Texas Health Science Center at San Antonio
Devjit Tripathy, MD
The University of Texas Health Science Center at San Antonio
18 participants (actual enrollment reported by the registry).
First Submitted
August 3, 2011
First Posted
September 23, 2011
Study Start
March 2011
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
June 30, 2018
Actual (reported)Study Completion
June 30, 2018
Actual (reported)Last Updated
July 3, 2025
Results First Posted
October 29, 2019
Record last verified: 2025-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: